Certain patient groups may be underrepresented or excluded from RCTs due to eligibility criteria, logistical barriers, ethical concerns or other reasons.
Examples of these potential groups are females, pregnant or breastfeeding females, older adults due to age or comorbidities, children, people […]
Quantify Research‘s very own Mary Rosenzweig will join speakers from Monsenso, Lundbeck and […]
Real-world evidence derived from data collected in routine clinical care is increasingly important for decision-makers in payer and regulatory environments.
Nordic health data has several characteristics that enable a globally unique research environment […]
As the number one provider of Nordic registry studies, Quantify sits at the heart of Scandinavia.
The Nordics typically refers to Northern European countries with similar history, culture and social structures.
They include Denmark, […]
Data that’s not fit-for-purpose can be scary, but here’s the good news – Nordic data has many characteristics that allow it to be considered high-quality for a wide range of purposes. These […]
The landscape of healthcare research is rapidly evolving, and social media is emerging as a valuable resource for real-world evidence (RWE) studies.
In one of Quantify’s publications, 𝐒𝐨𝐜𝐢𝐚𝐥 𝐌𝐞𝐝𝐢𝐚 𝐋𝐢𝐬𝐭𝐞𝐧𝐢𝐧𝐠 𝐟𝐨𝐫 𝐑𝐞𝐚𝐥-𝐖𝐨𝐫𝐥𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞: 𝐀 𝐍𝐨𝐯𝐞𝐥 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐨 𝐇𝐞𝐚𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐚𝐭𝐢𝐞𝐧𝐭’𝐬 𝐕𝐨𝐢𝐜𝐞, […]
Literature reviews are essential throughout the pharmaceutical product development lifecycle, from identifying therapeutic targets to assisting with regulatory and health technology assessment submissions and ultimately improving drug safety and patient outcomes at every stage.
This image presents the use cases for […]
Nordic registers have been described as a goldmine for producing Real-World Evidence (RWE) in health and welfare research.
The benefits of national registers are well-known; these administrative registers provide comprehensive longitudinal individual-level data with complete coverage for the total population.
Today, we’d […]
Quantify’s Mathias Lilja and Johan Mesterton are co-authors on a new study on cytarabine dosing for treating secondary and high-risk AML using a synthetic control arm study design.
Since 1980’s, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion […]
The Nordic region (often called Scandinavia) is home to some of the world’s best real-world data (RWD), driving the development of pharmaceuticals and medical devices. As high-quality RWD becomes increasingly important to regulators and payers, it is critical for real-world evidence […]